Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,731 | 230 | 1,482 |
| Samples | 769 | 138 | 621 |
| Peptides | 677 | 108 | 576 |
Function
KNL1 · Kinetochore scaffold 1
The protein encoded by this gene is a component of the multiprotein assembly that is required for creation of kinetochore-microtubule attachments and chromosome segregation. The encoded protein functions as a scaffold for proteins that influence the spindle assembly checkpoint during the eukaryotic cell cycle and it interacts with at least five different kinetochore proteins and two checkpoint kinases. In adults, this gene is predominantly expressed in normal testes, various cancer cell lines and primary tumors from other tissues and is ubiquitously expressed in fetal tissues. This gene was originally identified as a fusion partner with the mixed-lineage leukemia (MLL) gene in t(11;15)(q23;q14). Mutations in this gene cause autosomal recessive primary microcephaly-4 (MCPH4). Alternative splicing results in multiple transcript variants encoding different isoforms. Additional splice variants have been described but their biological validity has not been confirmed. [provided by RefSeq, Jan 2013].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 664 amino-acid changes on canonical ENST00000399668 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KNL1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KNL1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 35/612 6% |
| Melanoma | 8/210 4% | 78/1899 4% |
| Bladder Carcinoma | 0/58 0% | 34/956 4% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Colorectal Carcinoma | 19/143 13% | 88/3239 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 18/810 2% |
| Gastric Carcinoma | 9/74 12% | 42/1809 2% |
| Other Solid Cancers | 2/94 2% | 31/1515 2% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 26/1390 2% |
| Other Sarcomas | 2/69 3% | 13/699 2% |
| Neuroendocrine Tumour | 4/154 3% | 8/577 1% |
| Head and Neck Carcinoma | 3/85 4% | 22/1574 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 11/752 1% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Hepatocellular Carcinoma | 2/46 4% | 30/2210 1% |
| Burkitts Lymphoma | 2/32 6% | 1/196 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 28/2550 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 17/1592 1% |
| Glioma | 3/52 6% | 22/2127 1% |
| Plasma Cell Myeloma | 1/44 2% | 3/305 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Breast Carcinoma | 4/144 3% | 31/3264 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Biliary Tract Carcinoma | 1/54 2% | 8/950 1% |
Mutation Distribution
Where KNL1 is mutated · all tissues, split by cell line vs tissue
How many mutations in KNL1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,731 mutations in KNL1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|